SIRT With Tremelimumab and Durvalumab for Resectable HCC
SIRT With Tremelimumab and Durvalumab for Resectable HCC
Active, not recruiting · NCT05701488 · Registry updated 2026-08-13Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| SIRT With Tremelimumab and Durvalumab for Resectable HCC | Digestive System Diseases, Digestive System Neoplasms, Liver Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, adenocarcinoma, carcinoma, epithelial neoplasm, hepatocellular carcinoma, liver disorder, neoplasm | Active, not recruiting | Phase 1 | 2026-08-13 | NCT05701488 |
3 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| AstraZeneca | 806 |
| Jiping Wang, MD, PhD | 1 |
| Sirtex Medical | 9 |
3 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Beth Israel Deaconess Medical Center | Boston | United States | 462 |
| Cedars-Sinai Medical Center | Los Angeles | United States | 392 |
| Dana-Farber Cancer Institute | Boston | United States | 626 |